In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve Patient Outcomes” symposium held during the 2016 Annual Meeting of the Oncology Nursing Society, Dr. Ruth O’Regan discusses the biological rationale, development history, and dosing and administration of CDK 4/6 inhibitors in the ER+ metastatic breast cancer setting.
Earn accreditation for this activity at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7208
© 2016 Imedex, LLC.
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content